TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03589534

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: home pregnancy test
Description: Each participant will use 4 different home pregnancy tests
Study: NCT01386047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Clinical Prediction Rule (iCPR)
Description: Integrated clinical prediction rule for Strep Pharyngitis based on Walsh clinical prediction rule (CPR) criteria and rule for Pneumonia based on Hecklering CPR criteria.
Study: NCT01308593

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm XC
Description: Filler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: 26 units dosed one time
Study: NCT01419106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound (A point of care ultrasound protocol)
Description: Bedside ultrasound will be used to view any intraperitoneal bleeding, pleural fluid, cardiac abnormalities, or structural abnormalities of major blood vessels. The results of this test will then be used to determine the best course of treatment for the patient.
Study: NCT02398071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A water pressure threshold device (BreatheMAX)
Description: BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: A water pressure threshold device (BreatheMAX)
Description: BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
Study: NCT00881556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 mcg/kg/day for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV x 1 for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 4 mg/kg/day IV divided BID for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: 0.02-0.05 mg/kg for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 20 mg/m2 IV for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.03mg/kg/24 hours as continuous infusion for 4 days
Study: NCT03597334

Intervention type: BEHAVIORAL
Intervention: aerosol therapy
Description: Aerosol inhalation therapy refers to a local administration method in which a drug is made into aerosol particles having a very small diameter and is inhaled by a patient and the drug directly acts on the airway
Study: NCT00150462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered as an IV bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered as an IV bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered as an IV bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered as an IV bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered as an IV bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered as an IV bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered as an IV bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered as an IV bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered as an IV bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered as an IV bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered as an IV bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally prior to carfilzomib
Study: NCT05007288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restorative Eye Treatment (RET) cream
Description: RET cream will be applied topically to either the left of right eyelid once daily for 4 consecutive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INhance with Trihex Technology
Description: INhance will be applied topically to both eyelids once daily for 10 consecutive days after the SOC blepharoplasty surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INhance with Trihex Technology
Description: INhance will be applied topically to both eyelids once daily for 10 consecutive days after the SOC blepharoplasty surgery.
Study: NCT02298465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine ESWL
Description: ESWL to distal ureteric stone is performed in the supine position with the shockwave generator placed in the patient's buttock area. The aim is to direct the shockwaves through the greater and lesser sciatic foramina to reach the distal ureter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone ESWL
Description: ESWL to the distal ureteric stone is performed in the traditional prone position. The shockwave generator is placed on the patient's abdomen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Lithotripsy (ESWL)
Description: The ESWL machine we use is the Dornier S2 lithotriptor. ESWL is performed without any sedation or anesthesia under fluoroscopy. Painkillers are given upon request.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Lithotripsy (ESWL)
Description: The ESWL machine we use is the Dornier S2 lithotriptor. ESWL is performed without any sedation or anesthesia under fluoroscopy. Painkillers are given upon request.
Study: NCT04480073

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Customized CAD-CAM Titanium Mesh (Y-xoss CBR® by Reoss -Filderstadt - Germany) for Guided Bone Regeneration of atrophic alveolar ridges
Description: Step one:1) exposure of atrophic areas; 2) bone harvesting from mandible or calvarium; 3) filling the meshes with a mixture of the autogenous bone and particulated xenograft in a 1:1 ratio; 4) stabilization of the mesh with titanium micro-screws.~A post-operative cone-beam computed tomography (CBCT) will be done in all patients to have a reference point for the following controls.~6 months later, patients are re-evaluated with a new CBCT to check bone volumes of the regenerated tissues and to plan implant placement.~Step two: 1) removal of the meshes; 2) preparation of implant sites (one of which will be randomly chosen to obtain a bone biopsy for histomorphometric analysis); 3) implant placement.~3 months later, implants will be uncovered and the prosthetic phases will start.~Patients will be recalled 3, 6, and 12 months later, to assess peri-implant hard and soft tissue conditions, the stability of the reconstructed bone, and the onset of implant-related complications.
Study: NCT03468868

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program for people with MS
Description: The intervention consists of 30 minutes of resistance training and 30 minutes of cardio three times per week for 16 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program for people with MS
Description: The intervention consists of 30 minutes of resistance training and 30 minutes of cardio three times per week for 16 weeks.
Study: NCT03228693

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy and/or triamcinolone injection
Description: Subjects will have their blood drawn during the first study visit. Subsequently, a punch biopsy and/or triamcinolone injection will be given based on group timeline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy and/or triamcinolone injection
Description: Subjects will have their blood drawn during the first study visit. Subsequently, a punch biopsy and/or triamcinolone injection will be given based on group timeline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy and/or triamcinolone injection
Description: Subjects will have their blood drawn during the first study visit. Subsequently, a punch biopsy and/or triamcinolone injection will be given based on group timeline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy and/or triamcinolone injection
Description: Subjects will have their blood drawn during the first study visit. Subsequently, a punch biopsy and/or triamcinolone injection will be given based on group timeline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy and/or triamcinolone injection
Description: Subjects will have their blood drawn during the first study visit. Subsequently, a punch biopsy and/or triamcinolone injection will be given based on group timeline.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Excisional Biopsy
Description: Complete excision of an earlobe keloid will be taken.
Study: NCT04365309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg
Description: on the bases of standard treatment for the COVID-19, low-dose aspirin (100 mg/ day), orally，is added to.
Study: NCT04317066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Study: NCT03049488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-RSVRGP084-00-VP
Description: VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-RSVRGP084-00-VP
Description: VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-RSVRGP084-00-VP
Description: VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-RSVRGP084-00-VP
Description: VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-RSVRGP084-00-VP
Description: VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-RSVRGP084-00-VP
Description: VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aluminum Hydroxide Suspension
Description: Aluminum Hydroxide Suspension, alum, is an adjuvant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aluminum Hydroxide Suspension
Description: Aluminum Hydroxide Suspension, alum, is an adjuvant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aluminum Hydroxide Suspension
Description: Aluminum Hydroxide Suspension, alum, is an adjuvant.
Study: NCT00811668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP before SOMNOVentCR
Description: 4 weeks CPAP treatment, 1 week wash out period, 4 weeks SOMNOventCR treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOMNOventCR before CPAP
Description: 4 weeks SOMNOventCR treatment, 1 week wash out period, 4 weeks CPAP treatment
Study: NCT03146247

Intervention type: DRUG
Group type: OTHER
Intervention: Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet
Description: All patients are scheduled to receive Apremilast with a titration phase of one week, followed by 23 weeks of regular treatment.
Study: NCT04170309

Intervention type: DRUG
Intervention: Ceftobiprole medocaril
Description: Participants in whom treatment with Ceftobiprole medocaril has been completed

Intervention type: DRUG
Intervention: Ceftobiprole medocaril
Description: Participants in whom treatment with Ceftobiprole medocaril has been completed
Study: NCT03004300

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid maxillary expansion
Description: Device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion
Description: Device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion
Description: Device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Description: Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Description: Surgery
Study: NCT03649048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose Cisplatin
Description: Intravenous administration of High-Dose Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Cisplatin
Description: Intravenous administration of Low-Dose Cisplatin

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Participating centres are to follow their local radiation treatment planning and delivery techniques.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Participating centres are to follow their local radiation treatment planning and delivery techniques.
Study: NCT04639765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT without Personalization
Description: Intervention involves a video describing CBT without a message about personalization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT with Personalization
Description: Intervention involves a video describing CBT with a message about personalization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADM without Personalization
Description: Intervention involves a video describing antidepressant medication without a message about personalization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADM with Personalization
Description: Intervention involves a video describing antidepressant medication with a message about personalization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Treatment without Personalization
Description: Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication without a message about personalization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Treatment with Personalization
Description: Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication with a message about personalization.
Study: NCT03169348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir daclatasvir
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir/sofosbuvir
Description: oral tablets
Study: NCT03038737

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bre.flex
Description: In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon RDP is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK
Description: PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
Study: NCT01975207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Participants will be treated as per clinic's standard treatment for depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Intervention
Description: One of the major treatments for mild-moderate depressive disorders is cognitive behavioural therapy (CBT). It has been possible to operationalize some of this treatment and internet-based approaches to this have been developed. The most widely examined was developed in Australia and is termed MoodGYM (https://moodgym.anu.edu.au/welcome). This program has been widely studied, and these studies have shown it is very effective for many individuals in family practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression Treatment Pathway
Description: There has been a growing awareness in health care circles that certain high frequency, high cost addiction and mental health disorders may be best addressed via the systemic adoption of clinical pathways. A clinical pathway is defined as a multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to help a patient with a specific condition or set of symptoms move progressively through a clinical experience to positive outcomes. A clinical pathway incorporates guidelines, protocols and evidence informed best practice into everyday use for the patient and family.
Study: NCT01284205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mycobacterial Cell-Wall DNA Complex
Description: 8 mg/50 mL (sterile WFI) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guerin
Description: mg/50 mL (sterile saline) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
Study: NCT01568476

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal
Description: Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interneural
Description: Sciatic nerve blockade at the site of bifurcation
Study: NCT00759928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg once daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg twice daily by mouth
Study: NCT04470791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F(ab)2 antivenom therapy (antivipmyn®).
Description: Antivipmyn is an equine origin antivenom produced by Institute Bioclon in Mexico (Silanes Laboratories, México). The snake venoms used to create the F(ab')2 fragments are from Crotalus durissus and Bothrops asper. The number of doses of each patient depended on the classification and evolution, as indicated by the manufacturer for grade II envenoming: from 6 to 10 bottles of F(ab)2 antivenom therapy, intravenously, as an initial dose. One dose (bottle) consisted of 10 mL of polyvalent concentrated and modified horse antibodies treated by enzymatic digestion to neutralize the Bothrops asper venom to not less than 780 lethal dose 50 (LD50), and the Crotalus basiliscus venom to not less than 790 LD50.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: F(ab)2 antivenom therapy (antivipmyn®).
Description: Antivipmyn is an equine origin antivenom produced by Institute Bioclon in Mexico (Silanes Laboratories, México). The snake venoms used to create the F(ab')2 fragments are from Crotalus durissus and Bothrops asper. The number of doses of each patient depended on the classification and evolution, as indicated by the manufacturer for grade II envenoming: from 6 to 10 bottles of F(ab)2 antivenom therapy, intravenously, as an initial dose. One dose (bottle) consisted of 10 mL of polyvalent concentrated and modified horse antibodies treated by enzymatic digestion to neutralize the Bothrops asper venom to not less than 780 lethal dose 50 (LD50), and the Crotalus basiliscus venom to not less than 790 LD50.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local cryotherapy.
Description: Interval cryotherapy consisted of applying a plastic bag (the size of the bag depending on the size of the lesion, approximately 28 x 46 cm) two-thirds filled with crushed ice (frapped) wrapped in a towel applied for 20 minutes every 4 hours at the site of the snakebite throughout the hospital stay. New ice bags were used after 4 hours.
Study: NCT01771965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CB Intervention
Description: The Cognitive Behavioral (CB) intervention is a brief, manualized, tailored one-on-one single session lasting 45-60 minutes and administered by phone. An individual format was chosen to reduce the potential discomfort of stigma of individual concerns in the presence of others. The intervention targets a change in the beliefs that influence whether or not someone enters mental health or substance use treatment. During the session, participants will be given a brief introduction to CBT and informed that CBT is based on the theory that cognitions (i.e., thoughts/beliefs), feelings and behaviors all interact with each other;101, 102 therefore, thoughts about certain situations or things influence behavior. Since thoughts are modifiable, changing thoughts about situations may change behavior.
Study: NCT00950625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lignocaine
Description: 200 mg of intraperitoneal lignocaine will be given once during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lignocaine
Description: 200 mg of intraperitoneal lignocaine will be given once during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupevacaine
Description: 100 mg of bupevacaine will be given once during laparoscopic cholecystectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupevacaine
Description: 100 mg of bupevacaine will be given once during laparoscopic cholecystectomy
Study: NCT03895684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-2577 Seclidemstat
Description: Dose escalation and dose expansion of SP-2577.
Study: NCT04190693

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IMCY-0098 or placebo
Description: Long-term follow-up

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCY-0098 or placebo
Description: Long-term follow-up